Methylene blue treatment for cytokine release syndrome-associated vasoplegia following a renal transplant with rATG infusion: A case report and literature review

Experimental and Therapeutic Medicine

Volumn 9, Issue 5, 2015, Pages 1915-1920

  Denny, John T ^a   Burr, Andrew T ^a   Balzer, Fred ^b   Tse, James T ^a   Denny, Julia E ^c   Chyu, Darrick ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Virtua Memorial Hospital   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokine release syndrome; Cytokines; Distributive shock; Rabbit anti thymocyte globulin; Renal transplant complications; Shock; Thymoglobulin; Vasoplegia; Vasoplegic shock; Vasoplegic syndrome

Indexed keywords

ARGIPRESSIN; METHYLENE BLUE; NORADRENALIN; THYMOCYTE ANTIBODY;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; CYTOKINE RELEASE SYNDROME; DISEASE ASSOCIATION; FOLLOW UP; HEART INFARCTION; HUMAN; KIDNEY TRANSPLANTATION; MALE; PHYSICAL EXAMINATION; POSTOPERATIVE PERIOD; TREATMENT OUTCOME; VASOPLEGIA;

EID: 84925059989     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2349     Document Type: Article

References (42)

1. Teachey DT, Rheingold SR, Maude SL, et al: Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121: 5154-5157, 2013.
2. Sanofi Canada: Thymoglobulin® (Anti-thymocyte globulin [rabbit]) product monograph. http://products.sanofi.ca/en/thymoglobulin.pdf. Accessed Jan 25, 2015.
3. Mahmud N, Klipa D and Ahsan N: Antibody immunosuppressive therapy in solid-organ transplant: Part I. MAbs 2: 148-156, 2010.
4. Shanmugam G: Vasoplegic syndrome - the role of methylene blue. Eur J Cardiothorac Surg 28: 705-710, 2005.
5. Landry DW and Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 345: 588-595, 2001.
6. Friedrich M, Bräuer A, Tirilomis T, Lotfi S, Mielck F and Busch T: Methylene blue administration in severe systemic inflammatory response syndrome (SIRS) after thoracic surgery. Ann Thorac Cardiovasc Surg 8: 306-310, 2002.
7. Stawicki SP, Sims C, Sarani B, Grossman MD and Gracias VH: Methylene blue and vasoplegia: who, when, and how? Mini Rev Med Chem 8: 472-490, 2008.
8. Argenziano M, Chen JM, Cullinane S, et al: Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transplant 18: 814-817, 1999.
9. Taylor KM: SIRS - the systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 61: 1607-1608, 1996.
10. Downing SW and Edmunds LH Jr: Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 54: 1236-1243, 1992.
11. Flynn BC and Sladen RN: The use of methylene blue for vasodilatory shock in a pediatric lung transplant patient. J Cardiothorac Vasc Anesth 23: 529-530, 2009.
12. Levin RL, Degrange MA, Bruno GF, et al: Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 77: 496-499, 2004.
13. Beasley D and McGuiggin M: Interleukin 1 activates soluble guanylate cyclase in human vascular smooth muscle cells through a novel nitric oxide-independent pathway. J Exp Med 179: 71-80, 1994.
14. Mekontso-Dessap A, Houël R, Soustelle C, Kirsch M, Thebért D and Loisance DY: Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg 71: 1428-1432, 2001.
15. Robin JK, Oliver JA and Landry DW: Vasopressin deficiency in the syndrome of irreversible shock. J Trauma 54 (Suppl): S149-S154, 2003.
16. Boyle EM Jr, Pohlman TH, Johnson MC and Verrier ED: Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Ann Thorac Surg 63: 277-284, 1997.
17. Kwok ES and Howes D: Use of methylene blue in sepsis: A systematic review. J Intensive Care Med 21: 359-363, 2006.
18. Cauwels A, Janssen B, Buys E, Sips P and Brouckaert P: Anaphylactic shock depends on PI3K and eNOS-derived NO. J Clin Invest 116: 2244-2251, 2006.
19. Montrucchio G, Alloatti G and Camussi G: Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 80: 1669-1699, 2000.
20. Neugut AI, Ghatak AT and Miller RL: Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med 161: 15-21, 2001.
21. Gomes WJ, Carvalho AC, Palma JH, et al: Vasoplegic syndrome after open heart surgery. J Cardiovasc Surg (Torino) 39: 619-623, 1998.
22. Schulz R, Nava E and Moncada S: Induction and potential biological relevance of a Ca(2+)-independent nitric oxide synthase in the myocardium. Br J Pharmacol 105: 575-580, 1992.
23. Cremer J, Martin M, Redl H, et al: Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 61: 1714-1720, 1996.
24. Brown SG: Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis. Curr Opin Allergy Clin Immunol 5: 359-364, 2005.
25. Kemp SF and Lockey RF: Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol 110: 341-348, 2002.
26. Takakura K, Mizogami M and Fukuda S: Protamine sulfate causes endothelium-independent vasorelaxation via inducible nitric oxide synthase pathway. Can J Anaesth 53: 162-167, 2006.
27. Viaro F, Dalio MB and Evora PR: Catastrophic cardiovascular adverse reactions to protamine are nitric oxide/cyclic guanosine monophosphate dependent and endothelium mediated: should methylene blue be the treatment of choice? Chest 122: 1061-1066, 2002.
28. Donati A, Conti G, Loggi S, et al: Does methylene blue administration to septic shock patients affect vascular permeability and blood volume? Crit Care Med 30: 2271-2277, 2002.
29. Thiemermann C, Szabó C, Mitchell JA and Vane JR: Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proc Natl Acad Sci USA 90: 267-271, 1993.
30. Peer G, Itzhakov E, Wollman Y, et al: Methylene blue, a nitric oxide inhibitor, prevents haemodialysis hypotension. Nephrol Dial Transplant 16: 1436-1441, 2001.
31. Guttmann RD, Caudrelier P, Alberici G and Touraine JL: Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobuline and immunosuppression. Transplant Proc 29: 24S-26S, 1997.
32. Jeyarajah DR and Thistlethwaite JR, Jr.: General aspects of cytokine-release syndrome: timing and incidence of symptoms. Transplant Proc 25 (Suppl 1): 16-20, 1993.
33. Radhakrishnan J and Cohen DJ: Cytokine-release syndrome: general risk-factor modification - preparation of high-risk patients for use of OKT3. Transplant Proc 25 (Suppl 1): 60-62, 1993.
34. Rosenzweig EB, Starc TJ, Chen JM, et al: Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation 100 (Suppl): II182-II186, 1999.
35. Torgersen C, Dünser MW, Wenzel V, et al: Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med 36: 57-65, 2010.
36. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Critical Care Med 41: 580-637, 2013.
37. Alexander JH, Reynolds HR, Stebbins AL, et al; TRIUMPH Investigators: Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 297: 1657-1666, 2007.
38. Grubb KJ, Kennedy JL, Bergin JD, Groves DS and Kern JA: The role of methylene blue in serotonin syndrome following cardiac transplantation: a case report and review of the literature. J Thorac Cardiovasc Surg 144: e113-e116, 2012.
39. Licker M, Diaper J, Cartier V, et al: Clinical review: management of weaning from cardiopulmonary bypass after cardiac surgery. Ann Card Anaesth 15: 206-223, 2012.
40. Sloan EP, Koenigsberg MD, Philbin NB and Gao W; DCLHb Traumatic Hemorrhagic Shock Study Group; European HOST Investigators: Diaspirin cross-linked hemoglobin infusion did not influence base deficit and lactic acid levels in two clinical trials of traumatic hemorrhagic shock patient resuscitation. J Trauma 68: 1158-1171, 2010.
41. Leyh RG, Kofidis T, Strüber M, et al: Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J Thorac Cardiovasc Surg 125: 1426-1431, 2003.
42. Fischer GW and Levin MA: Vasoplegia during cardiac surgery: current concepts and management. Semin Thorac Cardiovasc Surg 22: 140-144, 2010.